Garry Menzel

Garry E.
Menzel is an Independent Director at Black Diamond Therapeutics, Inc. since 2017.
Holds director roles at Epilepsy Therapy Project and Royal College of Art.
Serves as Independent Non-Executive Director at Adaptimmune Therapeutics Plc since 2023.
Director at Roslin Cell Therapies Ltd. starting 2025.
Member-National Board at Epilepsy Foundation since 2003.
Operating Partner at GHO Capital Partners LLP since 2024.
Formerly President, Chief Executive Officer & Director at TCR² Therapeutics, Inc. from 2016 to 2023.
Managing Director at Credit Suisse Group AG in 2008.
Managing Director at The Goldman Sachs Group, Inc. in 2004.
Director at Institute for Systems Biology.
Independent Director at Stoke Therapeutics, Inc. from 2020 to 2026.
Chief Financial Officer at DaVita, Inc. from 2013 to 2015.
Chief Operating Officer at Regulus Therapeutics, Inc. from 2012 to 2013.
Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016.
Research Assistant at Smithkline Beecham Plc from 2004 to 2008.
Consultant at Bain & Co., Inc. from 1994 to 2004.
Education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge in 1988, and an MBA from Stanford Graduate School of Business in 1994.